AstraZeneca acquires Omniose to expand bacterial conjugate vaccine technology
AstraZeneca has completed its acquisition of US vaccine technology company Omniose, adding a proprietary bacterial bioconjugation platform to strengthen development of vaccines against serious infections and antimicrobial-resistant pathogens.
AstraZeneca announced on 10 November 2026 that it had acquired Omniose as a wholly owned subsidiary within its infectious disease business, bringing in a bioconjugation technology designed to link bacterial polysaccharide antigens to carrier proteins through biological manufacturing processes.
The acquisition builds on approximately three years of collaboration between the companies and expands AstraZeneca's capabilities in conjugate vaccine development for bacterial diseases and antimicrobial resistance, with financial terms undisclosed and no new vaccine regulatory approval associated with the transaction.
Field | Content |
Article Type | Deals |
Acquirer | AstraZeneca |
Acquired Company | Omniose |
Deal Type | Completed biotechnology company acquisition |
Announcement Date | 10 November 2026 |
Transaction Status | Completed |
Ownership Structure | Wholly owned subsidiary of AstraZeneca |
Target Company Country | United States |
Acquiring Business Area | Infectious disease |
Acquired Technology | Proprietary bacterial bioconjugation platform |
Technology Application | Conjugate vaccine development |
Scientific Approach | Biological linkage of bacterial polysaccharide antigens to carrier proteins |
Antigen Type | Bacterial polysaccharides |
Carrier Component | Carrier proteins |
Vaccine Modality | Bacterial conjugate vaccines |
Therapeutic Area | Infectious diseases |
Target Disease Category | Serious bacterial infections |
Additional Strategic Focus | Antimicrobial-resistant pathogens |
Prior Relationship | Approximately three years of research collaboration |
Purchase Price | Not disclosed |
Upfront Cash Consideration | Not disclosed |
Contingent Consideration | Not disclosed |
Total Transaction Value | Not disclosed |
Development Assets | Specific vaccine candidates not detailed in supplied summary |
Manufacturing Relevance | Biological production of polysaccharide-protein conjugates |
New Vaccine Approval | No |
What Happened | AstraZeneca completed its acquisition of Omniose and its bacterial vaccine bioconjugation technology. |
Why It Matters | The acquisition strengthens AstraZeneca's vaccine research capabilities in an area of continuing unmet need for bacterial infection prevention. |
Strategic Rationale | Integrate a specialised bioconjugation platform into AstraZeneca's infectious disease research and development capabilities. |
Transaction Distinction | Completed acquisition following an existing collaboration rather than a newly signed research agreement. |
Financial Clarification | The companies did not disclose acquisition consideration. |
Key Takeaway | AstraZeneca now owns Omniose and its bacterial conjugate vaccine technology platform. |
What to Watch | Technology integration, vaccine pipeline expansion, candidate development and progress against antimicrobial-resistant pathogens. |
Submitted Source | Fierce Biotech |
Submitted Source URL | https://www.fiercebiotech.com/biotech/astrazeneca-buys-omniose-bacterial-vaccine-technology |
Recommended Source | pharmaphorum |
Recommended Source URL | https://pharmaphorum.com/news/az-boosts-vaccine-capabilities-omniose-buy |
Relevant Date | 10 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
留言